戊酸Ingenol:一种治疗光化性角化病的新型外用药物

Future Prescriber Pub Date : 2013-01-16 DOI:10.1002/fps.99

Colin A Morton MD, FRCP(UK)

{"title":"戊酸Ingenol:一种治疗光化性角化病的新型外用药物","authors":"Colin A Morton MD, FRCP(UK)","doi":"10.1002/fps.99","DOIUrl":null,"url":null,"abstract":"<p>Ingenol mebutate is a once-daily topical treatment for actinic keratosis (AK) that is applied for only two or three days depending on body site. It has recently been approved by the FDA for the treatment of AK on the face, scalp, trunk and extremities and recommended for approval by the CHMP in September 2012. In this drug profile, the author reviews its mode of action, efficacy and tolerability and comments on the drug's likely place in practice. Copyright © 2013 John Wiley & Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 3","pages":"17-19"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.99","citationCount":"0","resultStr":"{\"title\":\"Ingenol mebutate: a novel topical agent for actinic keratosis\",\"authors\":\"Colin A Morton MD, FRCP(UK)\",\"doi\":\"10.1002/fps.99\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Ingenol mebutate is a once-daily topical treatment for actinic keratosis (AK) that is applied for only two or three days depending on body site. It has recently been approved by the FDA for the treatment of AK on the face, scalp, trunk and extremities and recommended for approval by the CHMP in September 2012. In this drug profile, the author reviews its mode of action, efficacy and tolerability and comments on the drug's likely place in practice. Copyright © 2013 John Wiley & Sons, Ltd.</p>\",\"PeriodicalId\":100566,\"journal\":{\"name\":\"Future Prescriber\",\"volume\":\"13 3\",\"pages\":\"17-19\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/fps.99\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future Prescriber\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/fps.99\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/fps.99","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Ingenol mebutate: a novel topical agent for actinic keratosis

Ingenol mebutate is a once-daily topical treatment for actinic keratosis (AK) that is applied for only two or three days depending on body site. It has recently been approved by the FDA for the treatment of AK on the face, scalp, trunk and extremities and recommended for approval by the CHMP in September 2012. In this drug profile, the author reviews its mode of action, efficacy and tolerability and comments on the drug's likely place in practice. Copyright © 2013 John Wiley & Sons, Ltd.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Prescriber

自引率

0.00%

发文量

期刊最新文献

Promising new drugs and drug targets for HIV treatment Treatment of rheumatoid arthritis: current and future Lurasidone: new development for the treatment of psychosis Sunovion: innovative medicines for areas of unmet clinical need Role and cost effectiveness of bariatric surgery in T2DM